French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, in combination with nivolumab for the adjuvant treatment of resected non-small cell lung cancer (NSCLC), with patient screening set to begin in the coming weeks.

TG4070 is the second candidate from the company's myvac platform and incorporates Transgene's proprietary AI-driven neoantigen prediction tool, SNIPER, and scalable cell-line manufacturing designed to accelerate vaccine supply and support broader platform deployment.

The company said its integrated development ecosystem is intended to optimise manufacturing, improve scalability and reproducibility, and potentially accelerate development timelines across multiple cancer indications.

SNIPER uses multiple computational models and a proprietary scoring framework to identify and prioritise highly immunogenic neoantigens for individualised vaccine design.

TG4070 is produced using a cell-line based manufacturing process that, compared with conventional chicken embryo fibroblast-based production, is designed to enable more efficient automated manufacturing, improved lead times and greater scalability while delivering comparable preclinical performance.

Transgene said the manufacturing approach will support broader deployment of the myvac platform and is planned for potential future TG4050 clinical trials, while TG4050 continues to progress in Phase 2 for head and neck squamous cell carcinoma (HNSCC) with topline data expected in the first quarter of 2028.

The Phase 1 study will evaluate the safety and tolerability of TG4070 plus nivolumab in resected NSCLC patients following neoadjuvant nivolumab and chemotherapy, targeting a patient population that remains at high risk of relapse despite advances in perioperative immunotherapy.